Agenus (AGEN) Non-Current Assets (2010 - 2026)
Agenus (AGEN) posted quarterly Non-Current Assets of $355000.0 for Q1 2026, down 99.8% year-over-year from $177.1 million in Q1 2025, and down 9.21% quarter-over-quarter from $391000.0 in Q4 2025.
Agenus (AGEN) Non-Current Assets (2010 - 2026) Analysis & Trends
Agenus' Non-Current Assets history runs 17 years deep, the most recent figure standing at $355000.0 for Q1 2026.
- In Q1 2026, Non-Current Assets fell 99.8% year-over-year to $355000.0; the TTM figure through Mar 2026 stood at $355000.0 (down 99.95% YoY), while the FY2025 annual figure was $391000.0, down 99.78% from the prior year.
- Non-Current Assets for Q1 2026 stood at $355000.0, down from $391000.0 in the prior quarter.
- The five-year high for Non-Current Assets was $212.9 million in Q2 2023, with the low at $355000.0 in Q1 2026.
- The 5-year median for Non-Current Assets is $180.7 million (2024), against an average of $155.0 million.
- The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 68.17% in 2022, then slumped 99.8% in 2026.
- Agenus' Non-Current Assets stood at $200.4 million in 2022, then increased by 0.53% to $201.5 million in 2023, then dropped by 10.32% to $180.7 million in 2024, then plunged by 99.78% to $391000.0 in 2025, then fell by 9.21% to $355000.0 in 2026.
- Business Quant data shows AGEN's Non-Current Assets at $355000.0 in Q1 2026, $391000.0 in Q4 2025, and $429000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | 318,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 318,000.00 |
| Mar 31, 2026 | 355,000.00 |
| Dec 31, 2025 | 391,000.00 |
| Sep 30, 2025 | 429,000.00 |
| Jun 30, 2025 | 171.88 Mn |
| Mar 31, 2025 | 177.06 Mn |
| Dec 31, 2024 | 180.70 Mn |
| Sep 30, 2024 | 188.33 Mn |
| Jun 30, 2024 | 192.41 Mn |
| Mar 31, 2024 | 196.21 Mn |
| Dec 31, 2023 | 201.50 Mn |
| Sep 30, 2023 | 209.92 Mn |
| Jun 30, 2023 | 212.86 Mn |
| Mar 31, 2023 | 207.17 Mn |
| Dec 31, 2022 | 200.43 Mn |
| Sep 30, 2022 | 177.59 Mn |
| Jun 30, 2022 | 167.24 Mn |
| Mar 31, 2022 | 150.82 Mn |
| Dec 31, 2021 | 133.98 Mn |
| Sep 30, 2021 | 129.24 Mn |